Daniel Nava

Prof. Daniel Nava

Radiology, Centro Infantil Boldrini, Campinas, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JRJuliana Ruas
Juliana Ruas
FSFelipe Luz Torres Silva
Felipe Luz Torres Silva
MEMayara Euzebio
Mayara Euzebio
TBTássia Oliveira Biazon
Tássia Oliveira Biazon
CDCamila Maia Martin Daiggi
Camila Maia Martin Daiggi
PJPatrícia Yoshioka Jotta
Patrícia Yoshioka Jotta
Pediatric tumors share few recurrent mutations and are instead characterized by copy number alterations (CNAs). The cell-free DNA (cfDNA) is a prominent source for the detection of cancer-specific biomarkers in plasma. We profiled CNAs in the tumor tissues for further evaluation of alterations in 1q, MYCN and 17p in the circulating tumor DNA (ctDNA) in the peripheral blood at diagnosis and follow-up using digital PCR. We report that among the different kinds of tumors (neuroblastoma, Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, leiomyosarcoma, osteosarcoma and benign teratoma), neuroblastoma presented the greatest amount of cfDNA, in correlation with tumor volume. Considering all tumors, cfDNA levels correlated with tumor stage, metastasis at diagnosis and metastasis developed during therapy. In the tumor tissue, at least one CNA (at CRABP2, TP53, surrogate markers for 1q and 17p, respectively, and MYCN) was observed in 89% of patients. At diagnosis, CNAs levels were concordant between tumor and ctDNA in 56% of the cases, and for the remaining 44%, 91.4% of the CNAs were present only in cfDNA and 8.6% only in the tumor. Within the cfDNA, we observed that 46% and 23% of the patients had MYCN and 1q gain, respectively. The use of specific CNAs as targets for liquid biopsy in pediatric patients with cancer can improve diagnosis and should be considered for monitoring of the disease response.

25 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JRJuliana Ruas
Juliana Ruas
FSFelipe Luz Torres Silva
Felipe Luz Torres Silva
MEMayara Euzebio
Mayara Euzebio
TBTássia Oliveira Biazon
Tássia Oliveira Biazon
CDCamila Maia Martin Daiggi
Camila Maia Martin Daiggi
PJPatrícia Yoshioka Jotta
Patrícia Yoshioka Jotta
There was an error in the original publication